Genomictree, Inc.
KKRX:2287609,400.00
KRW
+130.00
(+1.40%)
ISIN
KR7228760005
Return %
Stock
S&P 500
1Y
-50.63
14.20
3Y
-41.10
81.12
5Y
-28.52
68.34
Capital Structure
KRW
•
in mil. unless spec.Working Capital
KRW
•
in mil. unless spec.Growth Rates
KRW
•
in mil. unless spec.Quarterly Revenue
KRW
•
in mil. unless spec.Quarterly Earnings Per Share
KRW
•
in mil. unless spec.Quarterly Dividends Per Share
KRW
•
in mil. unless spec.Company Description
- Full Time Employees
- 76
- Sector
- Health services
- Industry
- Medical/Nursing services
- Address
- Daejeon South Korea
- IPO Date
- Jul 19, 2016
- Website
- genomictree.com
- Similar Companies
- Business
- Genomictree Inc. (228760.KS) develops and commercializes epigenomic biomarker-based molecular diagnostics for early cancer detection and infectious diseases; its core products include EarlyTect C, a non-invasive stool-based colorectal cancer screening test measuring methylated syndecan-2 DNA with 90% sensitivity and specificity, EarlyTect L for lung cancer risk assessment in pulmonary nodule patients via serum epigenetic markers, EarlyTect B for bladder cancer detection in hematuria patients using genetic and epigenetic markers, and AccuraDTect SARS-CoV-2 RT-qPCR kits with related nucleic acid transport media. The company, founded in 2000 and headquartered in Daejeon, South Korea, operates primarily in the biotechnology sector targeting healthcare providers, high-risk patients, and general screening populations across Asia and the United States. In recent developments, Genomictree established U.S. subsidiary Promis Diagnostics Inc. in 2019, which secured approximately $40.8 million in funding by 2020 for FDA clinical studies and premarket approval of colorectal and bladder cancer diagnostics, appointed Dr. Theo deVos as Senior Vice President in June 2025 to bolster U.S. operations, and received breakthrough device designation from the FDA for its EarlyTect BCD bladder cancer test in 2023 while launching laboratory-developed test services in the U.S.